Nuvalent, INC. 8-K Filing
Ticker: NUVL · Form: 8-K · Filed: Dec 16, 2025 · CIK: 1861560
Sentiment: neutral
Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-12-16 10:06:42
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVL The Nasdaq
- $315 million — om an undisclosed third party for up to $315 million. Information regarding Nuvalent's reven
Filing Documents
- d53736d8k.htm (8-K) — 22KB
- 0001193125-25-320150.txt ( ) — 132KB
- nuvl-20251216.xsd (EX-101.SCH) — 3KB
- nuvl-20251216_lab.xml (EX-101.LAB) — 18KB
- nuvl-20251216_pre.xml (EX-101.PRE) — 11KB
- d53736d8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. Nuvalent, Inc. (the "Company" or "Nuvalent") is aware of the announcement this morning by Royalty Pharma plc ("Royalty Pharma") that it has acquired a preexisting royalty interest in Nuvalent's neladalkib and zidesamtinib investigational product candidates from an undisclosed third party for up to $315 million. Information regarding Nuvalent's revenue share agreement with its scientific founder is available in Note 10 of Nuvalent's financial statements contained in Nuvalent's Annual Report on Form 10-K for the year ended December 31, 2024, and elsewhere in the Company's filings with the Securities and Exchange Commission. The "low single digit preexisting royalty" referred to in the Royalty Pharma press release is 1.5% of net sales of both neladalkib and zidesamtinib. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvalent, Inc. Date: December 16, 2025 By: /s/ Deborah A. Miller Deborah A. Miller, Ph.D. Chief Legal Officer and Secretary